## Mafalda A Videira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9184693/publications.pdf

Version: 2024-02-01

394421 377865 1,576 38 19 34 citations g-index h-index papers 39 39 39 2902 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles. Journal of Drug Targeting, 2002, 10, 607-613.	4.4	213
2	Immune system targeting by biodegradable nanoparticles for cancer vaccines. Journal of Controlled Release, 2013, 168, 179-199.	9.9	212
3	Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews, 2013, 65, 1816-1827.	13.7	187
4	In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. Journal of Controlled Release, 2015, 198, 91-103.	9.9	126
5	Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1208-1215.	3.3	107
6	Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1883-1892.	3.3	69
7	Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine, 2011, 6, 123-141.	3.3	62
8	Brain metastasization of breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 132-147.	7.4	60
9	Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 312-325.	7.4	52
10	Preclinical development of siRNA therapeutics: Towards the match between fundamental science and engineered systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 689-702.	3.3	48
11	Lymphatic uptake of lipid nanoparticles following endotracheal administration. Journal of Microencapsulation, 2006, 23, 855-862.	2.8	47
12	Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 110, 76-84.	4.3	46
13	Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome. Drug Discovery Today, 2015, 20, 1152-1158.	6.4	32
14	AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. Drug Delivery, 2018, 25, 961-972.	5.7	32
15	Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres. Biomaterials, 2009, 30, 5161-5169.	11.4	28
16	Cancer stem cells and personalized cancer nanomedicine. Nanomedicine, 2016, 11, 307-320.	3.3	27
17	Liquid-liquid extraction of clavulanic acid using an aqueous two-phase system of polyethylene glycol and potassium phosphate. Journal of Chromatography A, 1994, 668, 237-240.	3.7	25
18	Solid state formulations composed by amphiphilic polymers for delivery of proteins: characterization and stability. International Journal of Pharmaceutics, 2015, 486, 195-206.	5.2	25

#	Article	IF	CITATIONS
19	Self-assembly PEGylation assists SLN-paclitaxel delivery inducing cancer cell apoptosis upon internalization. International Journal of Pharmaceutics, 2016, 501, 180-189.	5.2	23
20	Experimental design towards an optimal lipid nanosystem: A new opportunity for paclitaxel-based therapeutics. European Journal of Pharmaceutical Sciences, 2013, 49, 302-310.	4.0	17
21	Micelle-based Systems for Pulmonary Drug Delivery and Targeting. Drug Delivery Letters, 2011, 1, 171-185.	0.5	15
22	Regulatory Aspects of Oncologicals: Nanosystems Main Challenges. Advances in Delivery Science and Technology, 2014, , 425-452.	0.4	14
23	miRNAs in Health and Disease: A Focus on the Breast Cancer Metastatic Cascade towards the Brain. Cells, 2020, 9, 1790.	4.1	14
24	Picturing Breast Cancer Brain Metastasis Development to Unravel Molecular Players and Cellular Crosstalk. Cancers, 2021, 13, 910.	3.7	14
25	Lipoplexes and Polyplexes: Gene Therapy. , 0, , 4335-4347.		13
26	Looking out for Cancer Stem Cells' Properties: The Value-Driving Role of CD44 for Personalized Medicines. Current Cancer Drug Targets, 2015, 14, 832-849.	1.6	13
27	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. Frontiers in Medicine, 2020, 7, 50.	2.6	11
28	Characterisation of DM- $\hat{l}^2$ -cyclodextrin:prednisolone complexes and their formulation as eye drops. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 80, 155-164.	1.6	7
29	Synthesis and biodistribution studies of two novel radioiodinated areno-annelated estra-1,3,5(10),16-tetraene-3-ols as promising estrogen receptor radioligands. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 559-569.	1.0	6
30	Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy. Procedia in Vaccinology, 2014, 8, 62-67.	0.4	6
31	Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets. Precision Nanomedicine, 2018, 1, 86-105.	0.8	6
32	Biodistribution of Lipid Nanoparticles: A Comparative Study of Pulmonary versus Intravenous Administration in Rats. Current Radiopharmaceuticals, 2012, 5, 158-165.	0.8	5
33	Repurposing Natural Dietary Flavonoids in the Modulation of Cancer Tumorigenesis: Decrypting the Molecular Targets of Naringenin, Hesperetin and Myricetin. Nutrition and Cancer, 2022, 74, 1188-1202.	2.0	5
34	Host-directed strategies using lipid nanoparticles to reduce mycobacteria survival. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	4
35	Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers. Onco, 2022, 2, 36-55.	0.6	3
36	Amphiphilic Polymers: Drug Delivery. , 0, , 186-202.		O

#	Article	IF	CITATIONS
37	Targeting AKT2 signalling events: improving therapeutic outcomes through cancer stemness modulation. Annals of Oncology, 2015, 26, ii25.	1.2	o
38	Micelle-based Systems for Pulmonary Drug Delivery and Targeting. Drug Delivery Letters, 2011, 1, 171-185.	0.5	0